Hiroshi Miyake

台灣諾華總裁 Frances Milnes日前接受台灣美國商會雜誌TOPICS專訪，暢談「自主領導、暢心無阻：諾華如何重新創想醫藥領域」，於6月號的台灣美國商會工商雜誌TOPICS露出。 除了諾華的公司策略，Fran也分享「暢心無阻推動心健康」導入經驗，和諾華專注於心血管疾病領域之努力，以及透過「患者創新與解決方案聯盟與合作夥伴關係平台」探討新藥可近性阻礙等議題。此外，她亦針對諾華如何展現企業社會責任方面的實踐進行分享，更多資訊請點閱以下內容。 https://lnkd.in/gMthNDSw #Novartistaiwan #AmchamTOPICS #UnblockedMovement #APPIS Frances Milnes, President of Novartis Taiwan, recently accepted the interview with TOPICS, the magazine of the American Chamber of Commerce in Taiwan, and talked about "Unbossed and Unblocked: How Novartis is Reimagining Medicine ". This story is published at the June edition of Taiwan Business TOPICS magazine. Besides sharing Novartis's corporate strategy, Fran also articulated how Novartis promotes "Unblocked Movement" , focuses on the efforts to enhance ASCVD disease awareness, and to discuss how to tackle obstacles for patient access through APPIS (Alliance & Partnerships for Patient Innovation & Solutions ) initiative with patient groups and other stakeholders. In addition, Fran also shared how Novartis contributes and implements its corporate social and sustainability responsibilities. Please visit the following link of the news story for details.  

58

📢【Taiwan Biotech Shines at the 2024 US BIO】📢 The North American Biotechnology Exhibition (US BIO), held in San Diego, California, USA, is a premier platform for showcasing the latest biotech innovations and promoting international collaboration! 🎉 Our exhibits included: 🔬 Five major technology platforms 💡 Seven innovative technologies 🏢 Taiwan Pavilion 🗣️ Taiwan Biotech Forum Additionally, the delegation visited several key institutions in Phoenix, including: 🧠 Barrow Neurological Institute 🧬 Translational Genomics Research Institute 🏥 Mayo Clinic These exchanges enabled Taiwan to discuss trends in brain and neurological disease treatment, genomics research, precision medicine, next-generation biopharmaceuticals, digital healthcare, and more with top US biotech institutions, creating endless business opportunities! 🤝 A total of 21 Taiwanese companies and academic institutions actively participated. The Taiwan Pavilion attracted significant international attention, leaving a lasting impression on the global stage. We look forward to more opportunities to promote Taiwan-US biotech exchanges and cooperation, creating a brighter future together! 🚀🌐 #2024USBIO #TaiwanBiotech #PrecisionMedicine #InternationalCooperation #DCB #BiotechInnovation #TaiwanUSExchange

7

After 4-day 1-on-1 meeting during BIO 2024, we are safely back to sweet homeland Taiwan. Thanks for all friends being meeting with us. In these meetings, Vacino Brain targeting (VBT) was the most popular technology which committed and requested by several big pharmas and biotechs. We will continue to work with them and support in much more drug load in the CNS. Our Vacino-ADmir, an miRNA-based drug for Alzheimer’s disease, was also popular and gained much interesting in this potential anti-neuroinflammation activity for treating neuroinflammation-related diseases, such as Parkinson’s disease and ALS. With collaboration with them, we do believe it will go for first-in-human trail in 2026. The most important asset is Vacino-CO, which is universal, oral available and adjuvant-free. For post-COVID-19 pandemic, we will work with government-level sector for continuing this project. Hopefully, we should catch on time for the next Disease X. Of course, we won’t miss the collaboration with pharma either. If interested in our company, please keep following with the reporting from recent Newsweek. #BIO2024 #VacinoBiotech #VacinoCO #VacinoADmir #VacinoBT #Newsweek #Taiwan #COVID19 #Universal #OralAvailable #Alzheimers #Neuroinflammation #CNSdelivery #Niosome #BiologicPenetratingBrainIsNotADream

45

4件のコメント

🔬 Exciting Research Discovery Alert! In a groundbreaking study, researchers have uncovered the pivotal role of lactobacilli in maintaining immune balance. Using the innovative "ASF" microbiota, containing a blend of two lactobacilli strains and six other lactobacilli strains, animal experiments revealed fascinating insights. Did you know that lactobacilli influence the concentration of a vital immune mediator called "interferon gamma"? Produced by lymphocytes, this mediator is a powerhouse in our defense against viruses, activating phagocytes and inducing crucial antigen expression. But here's the kicker: when experimental mice lacked lactobacilli in their intestines, symptoms of depression and anxiety intensified. Conversely, elevating lactobacilli levels in the gut helped regulate the mice's stress response, hinting at a promising trend towards reversing depression. This study underscores the profound impact of gut microbiota on mental health and highlights lactobacilli as potential players in therapeutic interventions. Stay tuned for more groundbreaking discoveries in the fascinating world of microbiome research! 🌱 💡 #Microbiome #HealthDiscovery #LactobacilliInAction

2

Pharmaceutical Giants Takeda, Astellas, and SMBC Launch Joint Venture to Boost Early-Stage Drug Discovery in Japan Takeda, Astellas Pharma, and Sumitomo Mitsui Banking Corporation have formed a joint venture in Japan to support early-stage pharmaceutical discovery programs and foster innovation in therapeutics. The venture, led by Toshio Fujimoto, will be based in Fujisawa and will focus on advancing drug discovery technologies, supporting entrepreneurship, and increasing the capacity to generate high-quality startup companies. Takeda and Astellas will contribute their expertise to the venture, with the ultimate goal of introducing groundbreaking therapeutics to the market. For more details please click the link! https://lnkd.in/d_t5pFCf #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

2

💡 👨‍🔬 Breakthrough Multi-Cancer Early Detection Research Findings at Prestigious American Society of Clinical Oncology (ASCO) Annual Meeting 2024 in Chicago 🌎 Dr. Le Son Tran, the SPOT-MAS R&D Team leader from Medical Genetics Institute Ho Chi Minh City and Gene Solutions is set to present breakthrough findings at the upcoming prestigious oncology conference this weekend. Since 2022, Gene Solutions kicked off the largest and most comprehensive multi-center prospective study, K-DETEK, to clinically validate the diagnostic performance of SPOT-MAS - recruiting 10,027 asymptomatic individuals aged 40 years or older. Our team is looking forward to share our findings at our poster session. The MCED team at Medical Genetics Institute Ho Chi Minh City and Gene Solutions developed a novel approach - Screening for the Presence Of Tumor by Methylation And Size (SPOT-MAS), which offers a comprehensive analysis through the integration of methylation, fragment length profile, DNA copy number aberration and end motif in a single library reaction. It was designed to simultaneously detect five common types of cancer, including liver, breast, colorectal, gastric, and lung cancer, and predict the tissue origin of cancer signal. Read more about our K-DETEK study abstract here: https://lnkd.in/gjNd9unN Future of Oncology: The strong performance of the K-DETEK study underpins the potential to shape the future direction of oncology research and treatment. The research team welcomes collaborative opportunities and anticipates our participation at ASCO Annual Meeting will provide a platform for collaboration among top oncology professionals. The conference will run from May 31 to June 4, at McCormick Place, Chicago USA and is also available online. It is an opportunity not to be missed for anyone interested in the forefront of cancer research. Our team is happy to meet up at ASCO in person - please DM us if you are keen to connect, or join us at our poster session: https://lnkd.in/gk83xwjG #MCED #SPOTMAS #KDETEK #earlydetectionsaveslives

92

1件のコメント

JT and Torii Pharmaceutical Co., Ltd. announced the initial results of a Phase 3 comparative study relative to pediatric patients with atopic dermatitis in Japan treated with JTE-061(tapinarof). We will aim to submit a manufacturing and marketing application for JTE-061 cream in Japan, based on the results of this and other clinical studies. For detailed results, please refer to the press release: https://lnkd.in/g2_9jhfi #JT #Torii Pharmaceutical #Pharma #tapinarof   小児アトピー性皮膚炎患者を対象とした現在開発中のJTE-061(tapinarof)について、日本国内で実施中の第Ⅲ相臨床試験（比較試験）の速報結果を得ました。 今後、本試験の成績等をもとに、日本国内における製造販売承認申請を目指します。 詳細な速報結果については、プレスリリースをご覧ください: https://lnkd.in/gt2KMrSX

175

1件のコメント

MediMabBio Signs MoU with PDC*line Pharma to Collaborate on Cancer Immunotherapy We are excited to announce a new memorandum of understanding (MOU) with PDC*line Pharma. This collaboration is aimed to explore the synergy between our MMB101/MFA011 and PDC*line Pharma’s plasmacytoid dendritic cell (PDC) cancer vaccines to revolutionize cancer treatment. Together, our promising drug candidates, targeting TIGIT and other immuno-oncology pathways, would enhance the efficacy of PDC cancer vaccines. By leveraging PDC*line Pharma’s expertise, we aim to boost the efficacy of our therapies and explore innovative treatment strategies. Stay connected for updates on our collaborative efforts to advance groundbreaking cancer treatments. #CancerResearch #Immunotherapy #Biotech #Partnership #MediMabBio #PDClinePharma

39

1件のコメント

#Collaborating to improve #cancer vaccines - PDC*line Pharma & MediMabBio have signed an MoU. Great news for both parties! You can read more about MediMabBio's development at the BioEscalator here https://bit.ly/MediMabBio

14

Academic researchers in Japan can now leverage the full power of the Sensoria Developer Kit to enable clinical trial, and the digital transformation of garments and footwear in Asia.

4

Uni-Bio – GBB – Pebble Accelerator Signed Agreement to Co-Develop Novel Weight-loss Drugs Hong Kong May 16, 2024 Great Bay Bio 大湾生物, Pebble (a subsidiary of #Tigermed) and Uni-Bio Science Group (HK690) 联康生物科技集团 officially signed a project cooperation agreement on jointly developing new weight loss drugs. The three parties will collaborate to innovate and build a complete ecological industrial chain of “Target discovery - #Antibody generation - #Druggability verification - #Process development - #Clinical pipeline stage – Commercialization”, and jointly explore and create a new therapeutic driving force for new target antibody drugs in the field of weight loss. Representatives from the Hong Kong Science and Technology Park (#HKSTP), Hong Kong’s largest science and technology business incubation base, attended the event to witness this event. Based on the company's super-powerful artificial intelligence platform, GBB's #AI antibody design platform make in-depth use of the "Fast Follow" and "First in Class" methods for antibody design, and directly predicts the structure of proteins through their amino acid sequence and provides a visual interface. It has broken through the industry's technical bottlenecks in terms of antibody generation, evaluation, and transformation, significantly reducing R&D trial and error costs and accelerating the process of new drug R&D. GBB was successfully admitted into the Elite Programme by HKSTP in May 24, 2023. At the same time, based on the strong #ecosystem of Pebble and the efficient production platform and marketing network of Uni-Bio, the three parties will complement each other's strengths and fully integrate the advantageous resources in drug development, clinical trials and marketing to jointly promote this landmark antibody drug to enter the clinical stage. This antibody drug can reduce or avoid many side effects that current drugs bring to patients, such as nausea, loss of appetite, suicidal tendencies, weight rebound after drug withdrawal, muscle loss, high frequency of administration, etc., seizing the tens of billions of dollars market in the field of weight loss, bringing new well-being to patients. For more info 👇 https://lnkd.in/dCBD5kSw #GreatBayBio #GBB #cooperation

38

KOREAN STARTUP NEWS. Korea's life science startups had another week filled with accomplishments! Here are the latest updates from the scene: • Prestige Biologics appoints Fionn Huang, formerly of Lonza Group, as new Director for international business development, aiming to accelerate CDMO sales in the US and China. • Liveome, a Medytox subsidiary, has registered a patent in China for its microbial gene therapy platform and LIV001, an inflammatory bowel disease treatment, expanding its intellectual property rights across key Asian markets. • Huniverse Global, a healthcare IT company, aims to expand its cloud-based precision medical hospital information system to Finland, leveraging the country's advanced healthcare system and IT infrastructure for global commercialization. • Huons Meditech highlighted its lithotripter, ASADAL-M1, at AUA 2024, drawing global interest for its advanced technology and non-invasive approach to treating urinary stones. To learn more about these startups, visit the articles linked in the comments! Source: Korea Biomedical Review #KICWashingtonDC #KoreaInnovationCenter #KICDC #KoreanStartup #Startup #LifeScience #Medtech

2

1件のコメント

Mr. Cai Lei, Founder and CEO of "Gradually Healing Mutual Aid Home," and Dr. Yin Ye, CEO of #BGI Group, announced their collaboration to establish a multi-omics research joint laboratory aimed at accelerating Amyotrophic lateral sclerosis (#ALS) research. ALS is a fatal motor neuron disease causing progressive nerve cell degeneration in the spinal cord and brain.   This collaboration will leverage genomics, spatiotemporal omics, and other multi-omics data to achieve breakthroughs in ALS and rare disease treatment, enhancing ALS diagnosis, assessing disease progression, and discovering new intervention targets. The initiative also aims to build an open data-sharing platform to attract more partners and improve the scientific research landscape.   Mr. Cai, an ALS patient and a well-known leader in the Chinese ALS patient community, emphasized the significant social value of this cooperation, which goes beyond academic and commercial interests. He praised Dr. Yin and the BGI team for their substantial scientific research assistance.   Dr. Yin emphasized that despite Mr. Cai’s physical limitations, he is determined and has clear goals, which has brought unprecedented hope to the field of rare disease research. The cooperation between BGI and Mr. Cai not only deepened the understanding of the genetic factors of ALS but also attracted society’s attention to rare diseases.   The second phase of free whole-genome sequencing tests for familial ALS patients officially commenced at the end of 2023, yielding exciting preliminary results. The program plans to offer high-depth whole-genome sequencing tests for 200 family lineages, with the testing costs jointly covered by Mr. Cai and Dr. Yin.   Learn more about this cooperation: https://t.co/YXdNZupNGJ   (Photo caption: Mr. Cai Lei, Founder and CEO of the Gradually Healing Mutual Aid Home Platform (fourth from the left), and Dr. Yin Ye, CEO and Executive Director of BGI Group (third from the right), unveiled the joint laboratory.)

69

[Published in April 2024] 📈 Vietnamese B2B pharmaceutical platform Buymed, known locally as Thuocsi, sees a remarkable 2x year-on-year revenue growth, hitting $76.4M in 2022 💸 Despite soaring revenues, Buymed's operating losses tripled to $15.3M due to increased administrative expenses and provisions for past obligations. 🌏 Buymed isn't just stopping at Vietnam; it's broadening its marketplace model to Cambodia and Thailand, empowering small pharmacies across Southeast Asia to access affordable drugs. 🔮 As Buymed navigates growing competition and cash flow concerns, it ventures into B2B2C franchising to enhance local drugstores' operations with advanced tech solutions. 💬 With Buymed's aggressive expansion and innovative strategies, can it redefine pharmaceutical distribution in Southeast Asia? What are the potential challenges and opportunities ahead?

1

【KBIC Company Topic】 Celaid has raised 1.2 billion yen in its Series A financing round to advance HSC-based cell and gene therapies and platform Celaid Therapeutics (Celaid), a Japan-based biotech developing Hematopoietic Stem Cell (HSC) therapies, today announced that it has raised an additional 460 million yen in its Series A extension round. This round was led by The University of Tokyo Edge Capital Partners (UTEC) and OSAKA University Venture Capital (OUVC) with participation from Techno Science and Joyo Capital Partners. This brings Celaid’s total raise to approximately 1.2 billion yen which includes existing Series A funding of 500 million yen and the recent 200 million yen from the NEDO Deep Tech Startup grant. Read more: https://lnkd.in/gk3kqyz2 #kbic #fbri #kobe #kansai #japan #healthcare #lifescience #innovation #hematopoieticstemcells Celaid Therapeutics

21